Home LiteratureArticle Details
PMID: 8657213 Published · ppublish English Clinical Trial Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients.

The New England journal of medicine ·Vol. 335 ·No. 3 ·1996-07-18 ·Pages 157-66

Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, Ciocci G, Carrier C, Stevens CE, Rubinstein P

Abstract

Transplantation of bone marrow from unrelated donors is limited by a lack of HLA-matched donors and the risk of graft-versus-host disease (GVHD). Placental blood from sibling donors can reconstitute hematopoiesis. We report preliminary results of transplantation using partially HLA-mismatched placental blood from unrelated donors. Twenty-five consecutive patients, primarily children, with a variety of malignant and non-malignant conditions received placental blood from unrelated donors and were evaluated for hematologic and immunologic reconstitution and GVHD. HLA matching was performed before transplantation by serologic typing for class I HLA antigens and low-resolution molecular typing for class II HLA alleles. In donor-recipient pairs who differed by no more than one HLA antigen or allele, high-resolution class II HLA typing was done retrospectively. Fordonor-recipient pairs who were mismatched for two HLA antigens or alleles, high-resolution typing was used prospectively to select the best match for HLA-DRB1. Twenty-four of the 25 donor-recipient pairs were discordant for one to three HLA antigens. In 23 of the 25 transplant recipients, the infused hematopoletic stem cells engrafted. Acute grade III GVHD occurred in 2 of the 21 patients who could be evaluated, and 2 patients had chronic GVHD. In vitro proliferative responses of T cells and B cells to plant mitogens were detected 60 days after transplantation. With a median follow-up of 12 1/2 months and a minimal follow-up of 100 days, the overall 100-day survival rate among these patients was 64 percent, and the overall event-free survival was 48 percent. HLA-mismatched placental blood from unrelated donors is an alternative source of stem cells for hematopoietic reconstitution in children.

MeSH Terms
Adolescent Adult Blood Banks Blood Donors Child Child, Preschool Disease-Free Survival Female Fetal Blood/cytology,immunology Graft vs Host Disease/etiology HLA Antigens/genetics Hematologic Diseases/therapy Hematopoietic Stem Cell Transplantation/adverse effects Histocompatibility Testing Humans Infant Infant, Newborn Male Placenta/blood supply Survival Rate
Chemicals
HLA Antigens
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Kurtzberg J
Pediatric Bone Marrow Transplant Program, Duke University Medical Center, Durham, NC 27710, USA.
Laughlin M
Graham M L
Smith C
Olson J F
Halperin E C
Ciocci G
Carrier C
Stevens C E
Rubinstein P
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
0028-4793
Published
1996-07-18
Pages
157-66
Language
English
Region
United States
NLM ID
0255562
Subset
IM
Grants
NHLBI NIH HHS · 1R18-HL48031 · United States
Corrections
CommentIn
CommentIn
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]